Propel Bio Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Propel Bio Management, LLC reported 29 stock positions worth $191.1 million. Its top holding was Plains GP (PAGP) at 16.2% of the portfolio, followed by Achieve Life Sciences (ACHV, 13.8%) and Corcept Therapeutics (CORT, 6.2%). Compared with Q1 2026, it opened 3 new positions, sold out of 12, added to 12 and reduced 10. The biggest buy was Achieve Life Sciences (ACHV, shares +7%) and the biggest sale an exit from Vor Biopharma (VOR).
- Most Recent 13F
- Q2 2026
- Location
- Los Angeles, CA
- CIK
- 0001969764
- Portfolio Value
- $191.1M (Q2 2026)
- SEC Filing
- 0001829126-26-008753 ↗ filed Aug 13, 2026
Holdings Value
Holdings 29 stocks · $191.1M
| PAGP Plains GP Holdings LP | 16.16% | 1,272,360 | $30.9M | No change |
| ACHV Achieve Life Sciences Inc. | 13.79% | 4,034,018 | $26.3M | Add +6.5% |
| CORT Corcept Therapeutics Inc. | 6.21% | 136,499 | $11.9M | Reduce -7.7% |
| PHAT Phathom Pharmaceuticals Inc. | 5.96% | 1,050,358 | $11.4M | Add +24.9% |
| DCTH Delcath Systems Inc. | 5.74% | 871,460 | $11.0M | Reduce -11.1% |
| MIST Milestone Pharmaceuticals Inc. | 5.21% | 7,429,590 | $10.0M | Add +80.4% |
| CMPS Compass Pathways PLC | 4.24% | 573,086 | $8.1M | Reduce -22.8% |
| KYTX Kyverna Therapeutics Inc. | 4.12% | 883,198 | $7.9M | Add +37.0% |
| ARTV Artiva Biotherapeutics Inc. | 3.54% | 696,436 | $6.8M | Add +375.8% |
| ABEO Abeona Therapeutics Inc. | 3.18% | 983,070 | $6.1M | Reduce -26.1% |
| AQST Aquestive Therapeutics Inc. | 3.14% | 1,442,397 | $6.0M | Add +102.9% |
| PALI Palisade Bio Inc. | 2.82% | 2,582,388 | $5.4M | Add +131.6% |
| IMUX Immunic Inc. | 2.61% | 325,022 | $5.0M | Add +38.6% |
| IVA Inventiva SA - ADR | 2.53% | 1,281,212 | $4.8M | Add +76.8% |
| SABS Sab Biotherapeutics Inc. | 2.20% | 1,076,578 | $4.2M | Add +6.3% |
| OBIO Orchestra Biomed Holdings Inc. | 2.02% | 896,701 | $3.9M | No change |
| CLDX Celldex Therapeutics Inc. | 2.02% | 103,695 | $3.9M | Reduce -21.1% |
| ZVRA Zevra Therapeutics Inc. | 1.90% | 253,544 | $3.6M | Reduce -10.2% |
| OCUL Ocular Therapeutix Inc. | 1.84% | 357,966 | $3.5M | Reduce -6.4% |
| FDMT 4D Molecular Therapeutics Inc. | 1.76% | 252,654 | $3.4M | Reduce -33.6% |
| OVID Ovid Therapeutics Inc. | 1.57% | 1,115,538 | $3.0M | Add +21.1% |
| EYPT Eyepoint Inc. | 1.43% | 191,745 | $2.7M | Reduce -11.2% |
| UPB Upstream Bio Inc. | 1.27% | 350,389 | $2.4M | Add +2.5% |
| SCYX Scynexis Inc. | 1.16% | 543,478 | $2.2M | New |
| SLN Silence Therapeutics PLC-ADR | 1.10% | 191,733 | $2.1M | New |
| LONA Leonabio Inc. | 0.72% | 149,279 | $1.4M | No change |
| MAZE Maze Therapeutics Inc. | 0.68% | 43,798 | $1.3M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 0.55% | 70,380 | $1.1M | Reduce -18.0% |
| SGMT Sagimet Biosciences Inc. Class A | 0.51% | 125,878 | $973K | New |
Portfolio Sells Q1 2026 → Q2 2026
| VOR Vor Biopharma Inc. | Sold out | 0.00% | −3.52 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −2.58 |
| OCS Oculis Holding AG | Sold out | 0.00% | −2.07 |
| TRVI Trevi Therapeutics Inc. | Sold out | 0.00% | −1.67 |
| CHRS Coherus Oncology Inc. | Sold out | 0.00% | −1.52 |
| KLRS Kalaris Therapeutics Inc. | Sold out | 0.00% | −1.08 |
| QURE Uniqure NV | Sold out | 0.00% | −1.08 |
| NUVB Nuvation Bio Inc. | Sold out | 0.00% | −0.89 |
| EVMN Evommune Inc. | Sold out | 0.00% | −0.81 |
| ALDX Aldeyra Therapeutics Inc. | Sold out | 0.00% | −0.78 |
| ABEO Abeona Therapeutics Inc. | Reduce -26.1% | 3.18% | −0.61 |
| CLDX Celldex Therapeutics Inc. | Reduce -21.1% | 2.02% | −0.59 |
| FDMT 4D Molecular Therapeutics Inc. | Reduce -33.6% | 1.76% | −0.50 |
| CNTB Connect Biopharma Holdings L | Sold out | 0.00% | −0.35 |
| EYPT Eyepoint Inc. | Reduce -11.2% | 1.43% | −0.32 |
| CRVS Corvus Pharmaceuticals Inc. | Reduce -18.0% | 0.55% | −0.24 |
| OCUL Ocular Therapeutix Inc. | Reduce -6.4% | 1.84% | −0.19 |
| MSLE Satellos Bioscience Inc. | Sold out | 0.00% | −0.04 |
| DCTH Delcath Systems Inc. | Reduce -11.1% | 5.74% | −0.03 |
| ZVRA Zevra Therapeutics Inc. | Reduce -10.2% | 1.90% | +0.24 |
| CMPS Compass Pathways PLC | Reduce -22.8% | 4.24% | +1.65 |
| CORT Corcept Therapeutics Inc. | Reduce -7.7% | 6.21% | +2.42 |
Portfolio Buys Q1 2026 → Q2 2026
| ACHV Achieve Life Sciences Inc. | Add +6.5% | 13.79% | +6.62 |
| ARTV Artiva Biotherapeutics Inc. | Add +375.8% | 3.54% | +2.94 |
| MIST Milestone Pharmaceuticals Inc. | Add +80.4% | 5.21% | +2.01 |
| PALI Palisade Bio Inc. | Add +131.6% | 2.82% | +1.57 |
| AQST Aquestive Therapeutics Inc. | Add +102.9% | 3.14% | +1.28 |
| SCYX Scynexis Inc. | New | 1.16% | +1.16 |
| SLN Silence Therapeutics PLC-ADR | New | 1.10% | +1.10 |
| IMUX Immunic Inc. | Add +38.6% | 2.61% | +0.96 |
| KYTX Kyverna Therapeutics Inc. | Add +37.0% | 4.12% | +0.60 |
| SGMT Sagimet Biosciences Inc. Class A | New | 0.51% | +0.51 |
| OVID Ovid Therapeutics Inc. | Add +21.1% | 1.57% | +0.29 |
| PHAT Phathom Pharmaceuticals Inc. | Add +24.9% | 5.96% | +0.07 |
| IVA Inventiva SA - ADR | Add +76.8% | 2.53% | +0.02 |
| SABS Sab Biotherapeutics Inc. | Add +6.3% | 2.20% | −0.25 |
| UPB Upstream Bio Inc. | Add +2.5% | 1.27% | −0.69 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 29 | $191.1M | PAGP, ACHV, CORT, PHAT, DCTH |
| Q1 2026 | 38 | $158.7M | PAGP, ACHV, PHAT, DCTH, CORT |
| Q4 2025 | 20 | $117.1M | PAGP, ACHV, PHAT, VRDN, MIST |
| Q3 2025 | 16 | $99.9M | PAGP, ACHV, AKRO, MIST, APLT |
| Q2 2025 | 16 | $82.4M | PAGP, ACHV, AKRO, PHAT, ABEO |
| Q1 2025 | 18 | $86.1M | PAGP, MDGL, AKRO, PHAT, ACHV |
| Q4 2024 | 21 | $100.7M | PAGP, MDGL, AKRO, ACHV, APLT |
| Q3 2024 | 21 | $172.4M | APLT, PAGP, PHAT, ACHV, TCRX |
| Q2 2024 | 24 | $154.2M | APLT, PAGP, TCRX, MDGL, ACHV |
| Q1 2024 | 28 | $171.8M | APLT, HIGH, TCRX, MDGL, ACHV |